Among 100 patients with persistent obesity (BMI ≥28 kg/m²) six months after metabolic and bariatric surgery, initiating liraglutide 3.0 mg/day at the 6-month postoperative mark produced 16.3% total weight loss by 18 months — more than triple the 5.3% seen in standard care controls. The 6-month group also led in achieving ≥15% TWL (64% of patients) and ≥20% TWL (24%), while preserving lean muscle mass and reducing liver enzyme ALT. Notably, the 9-month group achieved the highest proportion reaching BMI <28 kg/m² (52%), suggesting a nuanced timing-efficacy relationship worth investigating further.
Bariatric surgery patients who fail to reach weight goals by 6 months represent a clinically underserved population where the evidence base for adjunct pharmacotherapy has been thin. This prospective trial fills a meaningful gap, particularly as GLP-1 receptor agonists increasingly become frontline obesity tools. The finding that earlier initiation amplifies outcomes aligns with the hypothesis that the post-surgical metabolic environment — altered gut hormone signaling, reduced caloric intake — may potentiate GLP-1 drug effects. Reductions in MASLD and hyperuricemia remission rates add clinically meaningful secondary weight to the results.
Critical caveats: the study is small (n=25 per arm), Chinese-population-specific BMI thresholds limit global generalizability, randomization details are unclear, and the authors themselves flag that causality is unestablished. This is a promising signal, not definitive guidance — but it should accelerate larger RCTs examining pharmacotherapy timing windows post-surgery.